Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2018

Open Access 01-12-2018 | Primary research

Exploration of methylation-driven genes for monitoring and prognosis of patients with lung adenocarcinoma

Authors: Chundi Gao, Jing Zhuang, Huayao Li, Cun Liu, Chao Zhou, Lijuan Liu, Changgang Sun

Published in: Cancer Cell International | Issue 1/2018

Login to get access

Abstract

Background

As one of the most common malignant tumors in humans, lung cancer has experienced a gradual increase in morbidity and mortality. This study examined prognosis-related methylation-driven genes specific to lung adenocarcinoma (LUAD) to provide a basis for prognosis prediction and personalized targeted therapy for LUAD patients.

Methods

The methylation and survival time data from LUAD patients in the TCGA database were downloaded. The MethylMix algorithm was used to identify the differential methylation status of LUAD and adjacent tissues based on the β-mixture model to obtain disease-related methylation-driven genes. A COX regression model was then used to screen for LUAD prognosis-related methylation-driven genes, and a linear risk model based on five methylation-driven gene expression profiles was constructed. A methylation and gene expression combined survival analysis was performed to further explore the prognostic value of 5 genes independently.

Results

There were 118 differentially expressed methylation-driven genes in the LUAD tissues and adjacent tissues. Five of the genes, CCDC181, PLAU, S1PR1, ELF3, and KLHDC9, were used to construct a prognostic risk model. Overall, the survival time was significantly lower in the high-risk group compared with that in the low-risk group (P < 0.05). In addition, the methylation and gene expression combined survival analysis found that the combined expression levels of the genes CCDC181, PLAU, and S1PR1 as well as KLHDC9 alone can be used as independent prognostic markers or drug targets.

Conclusion

Our findings provide an important bioinformatic basis and relevant theoretical basis for guiding subsequent LUAD early diagnosis and prognosis assessments.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRef
2.
Dias M, Linhas R, Campainha S, Conde S, Barroso A. Lung cancer in never-smokers—what are the differences? Acta Oncol. 2017;56(7):931–5.CrossRef
3.
Sun S, Schiller J, Gazdar A. Lung cancer in never smokers—a different disease. Nat Rev Cancer. 2007;7(10):778–90.CrossRef
4.
Yoshizawa A, Motoi N, Riely G, Sima C, Gerald W, Kris M, Park B, Rusch V, Travis W. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653–64.CrossRef
5.
Sakashita S, Sakashita M, Sound Tsao M. Genes and pathology of non-small cell lung carcinoma. Semin Oncol. 2014;41(1):28–39.CrossRef
6.
Raso M, Behrens C, Herynk M, Liu S, Prudkin L, Ozburn N, Woods D, Tang X, Mehran R, Moran C, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009;15(17):5359–68.CrossRef
7.
Siegelin M, Borczuk A. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest. 2014;94(2):129–37.CrossRef
8.
Song J, Ye A, Jiang E, Yin X, Chen Z, Bai G, Zhou Y, Liu J. Reconstruction and analysis of the aberrant lncRNA–miRNA–mRNA network based on competitive endogenous RNA in CESC. J Cell Biochem. 2018;119(8):6665–73.CrossRef
9.
10.
Beland F. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci. 2009;66(14):2249–61.CrossRef
11.
Laurent L, Ren B, Loring J, Fan J. Unraveling epigenetic regulation in embryonic stem cells. Cell Stem Cell. 2008;2(2):123–34.CrossRef
12.
Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–56.CrossRef
13.
Feng H, Zhang Z, Wang X, Liu D. Identification of DLC-1 expression and methylation status in patients with non-small-cell lung cancer. Mol Clin Oncol. 2016;4(2):249–54.CrossRef
14.
Guo F, Guo L, Li Y, Zhou Q, Li Z. MALAT1 is an oncogenic long non-coding RNA associated with tumor invasion in non-small cell lung cancer regulated by DNA methylation. Int J Clin Exp Pathol. 2015;8(12):15903–10.PubMedPubMedCentral
15.
Li J, Jia X, Liu J, Liu J, Zhao H. Relationship of EGFR DNA methylation with the severity of non-small cell lung cancer. Genet Mol Res. 2015;14(4):11915–23.CrossRef
16.
Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, Minamoto T. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin Cancer Res. 2010;16(8):2418–26.CrossRef
17.
Feng H, Zhang Z, Qing X, Wang X, Liang C, Liu D. Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC). Exp Mol Pathol. 2016;100(1):109–13.CrossRef
18.
Zhang X, Yang X, Wang J, Liang T, Gu Y, Yang D. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer. Int J Clin Exp Pathol. 2015;8(9):11452–7.PubMedPubMedCentral
19.
Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–77.
20.
Gevaert O. MethylMix: an R package for identifying DNA methylation-driven genes. Bioinformatics. 2015;31(11):1839–41.CrossRef
21.
Gevaert O, Tibshirani R, Plevritis S. Pancancer analysis of DNA methylation-driven genes using MethylMix. Genome Biol. 2015;16:17.CrossRef
22.
Huang DW, Sherman B, Lempicki R. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.CrossRef
23.
Kamburov A, Pentchev K, Galicka H, Wierling C, Lehrach H, Herwig R. ConsensusPathDB: toward a more complete picture of cell biology. Nucleic Acids Res. 2011;39(Database:issue):D712–7.
24.
Kamburov A, Stelzl U, Lehrach H, Herwig R. The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res. 2013;41(Database issue):D793–800.CrossRef
25.
Lossos I, Czerwinski D, Alizadeh A, Wechser M, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828–37.CrossRef
26.
Bao Z, Li M, Wang J, Zhang C, Wang H, Yan W, Liu Y, Zhang W, Chen L, Jiang T. Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling. CNS Neurosci Ther. 2014;20(2):112–8.CrossRef
27.
Cheng W, Ren X, Cai J, Zhang C, Li M, Wang K, Liu Y, Han S, Wu A. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Oncotarget. 2015;6(30):29285–95.PubMedPubMedCentral
28.
Gardiner N, Jogai S, Wallis A. The revised lung adenocarcinoma classification—an imaging guide. J Thorac Dis. 2014;6(Suppl 5):S537–46.PubMedPubMedCentral
29.
Sardenberg R, Mello E, Younes R. The lung adenocarcinoma guidelines: what to be considered by surgeons. J Thorac Dis. 2014;6(Suppl 5):S561–7.PubMedPubMedCentral
30.
Dobersch S, Romero-Olmedo A, Barreto G. Epigenetics in lung cancer diagnosis and therapy. Cancer Metast Rev. 2015;34(2):229–41.CrossRef
31.
Chang S, Wang H, Yang S, Lai K, Lee T. Prognostic values of EPDR1 hypermethylation and its inhibitory function on tumor invasion in colorectal cancer. Cancers. 2018;10:10.CrossRef
32.
Baylin S, Jones P. A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer. 2011;11(10):726–34.CrossRef
33.
Robles A, Arai E, Mathé E, Okayama H, Schetter A, Brown D, Petersen D, Bowman E, Noro R, Welsh J, et al. An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers. J Thorac Oncol. 2015;10(7):1037–48.CrossRef
34.
Sugimoto N, Maehara K, Yoshida K, Yasukouchi S, Osano S, Watanabe S, Aizawa M, Yugawa T, Kiyono T, Kurumizaka H, et al. Cdt1-binding protein GRWD1 is a novel histone-binding protein that facilitates MCM loading through its influence on chromatin architecture. Nucleic Acids Res. 2015;43(12):5898–911.CrossRef
35.
Haldrup C, Mundbjerg K, Vestergaard E, Lamy P, Wild P, Schulz W, Arsov C, Visakorpi T, Borre M, Høyer S, et al. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol. 2013;31(26):3250–8.CrossRef
36.
Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 2005;14(1):105–12.PubMed
37.
Sliva D. Suppression of cancer invasiveness by dietary compounds. Mini Rev Med Chem. 2008;8(7):677–88.CrossRef
38.
Di Bernardo M, Matakidou A, Eisen T, Houlston R. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis. Lung Cancer. 2009;65(2):237–41.CrossRef
39.
Mendelson K, Evans T, Hla T. Sphingosine 1-phosphate signalling. Development. 2014;141(1):5–9.CrossRef
40.
Li M, Sanchez T, Yamase H, Hla T, Oo M, Pappalardo A, Lynch K, Lin C, Ferrer F. S1P/S1P1 signaling stimulates cell migration and invasion in Wilms tumor. Cancer Lett. 2009;276(2):171–9.CrossRef
41.
Degagné E, Pandurangan A, Bandhuvula P, Kumar A, Eltanawy A, Zhang M, Yoshinaga Y, Nefedov M, de Jong P, Fong L, et al. Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. J Clin Invest. 2014;124(12):5368–84.CrossRef
42.
Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, Shen S, Priceman S, Kujawski M, Pal S, et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell. 2012;21(5):642–54.CrossRef
43.
Yoshida Y, Nakada M, Harada T, Tanaka S, Furuta T, Hayashi Y, Kita D, Uchiyama N, Hayashi Y, Hamada J. The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J Neurooncol. 2010;98(1):41–7.CrossRef
44.
Wang H, Yu Z, Huo S, Chen Z, Ou Z, Mai J, Ding S, Zhang J. Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer. Int J Biochem Cell Biol. 2018;94:98–106.CrossRef
45.
Zhang D, Qu L, Ma L, Zhou Y, Wang G, Zhao X, Zhang C, Zhang Y, Wang M, Zhang M, et al. Genome-wide identification of transcription factors that are critical to non-small cell lung cancer. Cancer Lett. 2018;434:132–43.CrossRef
46.
Zheng L, Xu M, Xu J, Wu K, Fang Q, Liang Y, Zhou S, Cen D, Ji L, Han W, et al. ELF3 promotes epithelial–mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma. Cell Death Dis. 2018;9(3):387.CrossRef
Metadata
Title
Exploration of methylation-driven genes for monitoring and prognosis of patients with lung adenocarcinoma
Authors
Chundi Gao
Jing Zhuang
Huayao Li
Cun Liu
Chao Zhou
Lijuan Liu
Changgang Sun
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2018
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-018-0691-z

Other articles of this Issue 1/2018

Cancer Cell International 1/2018 Go to the issue

Primary research

An actin-binding protein ESPN is an independent prognosticator and regulates cell growth for esophageal squamous cell carcinoma

Primary research

MiR-144-3p promotes the tumor growth and metastasis of papillary thyroid carcinoma by targeting paired box gene 8

Primary Research

Effect of long non-coding RNA Gas5 on proliferation, migration, invasion and apoptosis of colorectal cancer HT-29 cell line

Primary Research

MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer

Review

Targeting FBPase is an emerging novel approach for cancer therapy

Primary research

Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits